secwatch.observer — SEC 8-K summary
======================================

Issuer:     MeiraGTx Holdings plc (MGTX)
CIK:        0001735438
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001558370-23-018914
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MeiraGTx reports Q3 net loss $44.3M; Sanofi invests $30M at $7.50/share
-----------------------------------------------------------------------

- Sanofi purchased $30M of ordinary shares at $7.50/share; ROFN for Riboswitch platform on CNS, I&I, metabolic targets including GLP-1 and Xerostomia.
- Q3 net loss $44.3M ($0.74 per share) vs $37.3M ($0.83) prior year; license revenue $5.1M.
- R&D expenses rose 65% to $27.9M driven by manufacturing costs and Janssen collaboration changes.
- Cash $64.4M plus $22M Janssen receivables and $30M Sanofi investment; runway into mid-2025.
- Phase 3 XLRP trial fully enrolled with IND transferred to Janssen; Phase 2 Xerostomia and Parkinson's studies ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1735438/000155837023018914/0001558370-23-018914-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1735438/000155837023018914/mgtx-20231114x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-018914

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer